Drug Trial Radar · NCT07725939
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
402
Planned (sponsor's estimate)
Start
Jul 27, 2026
Primary completion
Jun 29, 2029
Study completion Jun 29, 2029
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jul 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.
Conditions
- Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Interventions
GalvokimigBiological
Drug: Galvokimig Pharmaceutical form: Solution for injection
PlaceboBiological
Drug: Placebo Pharmaceutical form: Solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from treatment assignment to first moderate or severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD)Time frame: Up to Week 60
Locations
26 sites in 2 countries. Site status is shown where the registry gives one.
Copd01 50021
Encino, California · Recruiting
Copd01 50016
Westminster, California · Recruiting
Copd01 50011
Miami, Florida · Recruiting
Copd01 50008
Rincon, Georgia · Recruiting
Copd01 50017
Charlotte, North Carolina · Recruiting
Copd01 50003
Columbus, Ohio · Recruiting
Copd01 50019
Medford, Oregon · Recruiting
Copd01 50002
DuBois, Pennsylvania · Recruiting
Copd01 50020
North Charleston, South Carolina · Recruiting
Copd01 50004
Rock Hill, South Carolina · Recruiting
Copd01 50009
Spartanburg, South Carolina · Recruiting
Copd01 50010
Union, South Carolina · Recruiting
Copd01 50001
Boerne, Texas · Recruiting
Copd01 50006
McKinney, Texas · Recruiting
Copd01 50005
Tomball, Texas · Recruiting
Copd01 50013
Seattle, Washington · Recruiting
Copd01 20001
Beijing, China · Recruiting
Copd01 20004
Chengdu, China · Recruiting
Copd01 20006
Guangzhou, China · Recruiting
Copd01 20003
Hangzhou, China · Recruiting
Copd01 20005
Hangzhou, China · Recruiting
Copd01 20002
Nanchang, China · Recruiting
Copd01 20008
Shenzhen, China · Recruiting
Copd01 20012
Shijiazhuang, China · Recruiting
Copd01 20015
Yangzhou SHI, China · Recruiting
Copd01 20007
Zhanjiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.